Global Hyperphosphatemia Drugs Market Growth 2023-2029

Global Hyperphosphatemia Drugs Market Growth 2023-2029

hosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.

LPI (LP Information)' newest research report, the “Hyperphosphatemia Drugs Industry Forecast” looks at past sales and reviews total world Hyperphosphatemia Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Hyperphosphatemia Drugs sales for 2023 through 2029. With Hyperphosphatemia Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hyperphosphatemia Drugs industry.

This Insight Report provides a comprehensive analysis of the global Hyperphosphatemia Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hyperphosphatemia Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Hyperphosphatemia Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hyperphosphatemia Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hyperphosphatemia Drugs.

The global Hyperphosphatemia Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Major factors driving the market include rise in prevalence of chronic diseases, high unmet medical needs, increase in the number of people undergoing dialysis, large geriatric population, and surge in public awareness worldwide. Diabetes and hypertension are the main causes of renal failure, which leads to hyperphosphatemia. However, stringent regulations by regulatory bodies such as the Food and Drug Administration (FDA), non-adherence to treatment regimens, and rise in side effects of hyperphosphatemia drugs are likely to inhibit the market. According to FDA use of hyperphosphatemia drugs for the treatment of high or low phosphorus levels in the human body is neither safe nor effective. High growth potential in untapped economies, such as India, China, South Africa, and Brazil, is expected to create lucrative opportunities for key players. Rise in geriatric population and increase in cases of osteoporosis in Asia Pacific is anticipated to drive the market. Osteoporosis is often undertreated and underdiagnosed, which is driving the hyperphosphatemia drugs market in Asia Pacific. The available calcium, lanthanum, sevelamer, and iron-based drugs for treating hyperphosphatemia are associated with certain side effects. The long-term use of calcium-based drugs such as calcium carbonate and calcium acetate can cause vascular calcification.

This report presents a comprehensive overview, market shares, and growth opportunities of Hyperphosphatemia Drugs market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Aluminum Phosphate Binder
Iron Phosphate Binder
Magnesium Phosphate Binder
Calcium Phosphate Binder

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Keryx Biopharmaceuticals
Sanofi
Takeda
Vifor Pharma
Amgen
Bayer

Key Questions Addressed in this Report

What is the 10-year outlook for the global Hyperphosphatemia Drugs market?

What factors are driving Hyperphosphatemia Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Hyperphosphatemia Drugs market opportunities vary by end market size?

How does Hyperphosphatemia Drugs break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.